ALRN Stock Forecast 2025-2026
Distance to ALRN Price Targets
ALRN Price Momentum
10 Quality Stocks Worth Considering Now
Researching Aileron (ALRN) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ALRN and similar high-potential opportunities.
Latest ALRN Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, ALRN has a bullish consensus with a median price target of $13.00 (ranging from $7.00 to $19.00). Currently trading at $2.01, the median forecast implies a 546.8% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Aydin Huseynov at Ladenburg Thalmann, projecting a 845.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ALRN Analyst Ratings
ALRN Price Target Range
Latest ALRN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ALRN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 18, 2024 | Ladenburg Thalmann | Aydin Huseynov | Buy | Maintains | $19.00 |
| Dec 1, 2023 | Ladenburg Thalmann | Buy | Upgrade | $0.00 |
Aileron Therapeutics, Inc. (ALRN) Competitors
The following stocks are similar to Aileron based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Aileron Therapeutics, Inc. (ALRN) Financial Data
Aileron Therapeutics, Inc. has a market capitalization of $45.72M with a P/E ratio of -0.6x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -44.3%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Aileron Therapeutics, Inc. (ALRN) Business Model
About Aileron Therapeutics, Inc.
Develops biopharmaceuticals for unmet medical needs.
Aileron Therapeutics focuses on developing innovative treatments for orphan diseases, primarily in the fields of pulmonary and fibrosis indications. The company generates revenue through the advancement of its drug candidates, such as LTI-03 and LTI-01, which are in various stages of clinical trials, with the potential for partnerships or licensing agreements once products are commercialized.
The company has a robust pipeline that includes preclinical programs targeting cystic fibrosis and systemic fibrosis. Established in 2001 and based in Austin, Texas, Aileron Therapeutics was previously known as Renegade Therapeutics, highlighting its evolution and commitment to addressing critical health challenges.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
15
CEO
Dr. James Brian Windsor Ph.D.
Country
United States
IPO Year
2017
Website
www.aileronrx.comAileron Therapeutics, Inc. (ALRN) Latest News & Analysis
Aileron Therapeutics has rebranded to Rein Therapeutics, focusing on therapies for orphan pulmonary and fibrosis conditions. Shares will trade as "RNTX" on Nasdaq starting January 13, 2025.
Rein Therapeutics' focus on orphan pulmonary and fibrosis therapies could attract investors seeking growth in niche markets. The Nasdaq listing under "RNTX" may enhance visibility and liquidity.
Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
4 months agoAileron Therapeutics reported positive safety and biomarker data from Cohort 2 of its Phase 1b trial for LTI-03 in idiopathic pulmonary fibrosis. Planning for a Phase 2 trial is underway.
Positive trial results for LTI-03 in IPF patients enhance Aileron's growth prospects, increasing investor confidence and potential stock value ahead of the planned Phase 2 trial.
Aileron Therapeutics reported positive Phase 1b results for LTI-03 in idiopathic pulmonary fibrosis, showing reduced profibrotic proteins and good tolerability. A Phase 2 trial is planned.
Positive trial results for LTI-03 in idiopathic pulmonary fibrosis may lead to significant advancements in treatment options, boosting Aileron Therapeutics' stock value and investor confidence.
Aileron Therapeutics has entered an exclusive option agreement with Advancium to evaluate ALRN-6924 as a potential treatment for retinoblastoma, a rare pediatric eye cancer.
The exclusive option agreement for ALRN-6924 highlights Aileron Therapeutics' strategic pivot into pediatric oncology, potentially opening new markets and increasing its valuation amidst growing interest in rare diseases.
Aileron Therapeutics presented positive data from its Phase 1b trial of LTI-03 for IPF, showing favorable trends in seven biomarkers. Cohort 2 enrollment is complete, with topline data expected soon.
Positive trial results for LTI-03 in IPF may indicate a promising treatment, potentially boosting Aileron's stock value and attracting interest from investors in the biotech sector.
Aileron Therapeutics has completed enrollment in Cohort 2 of its Phase 1b trial for LTI-03 in IPF patients, following positive trends in biomarkers from Cohort 1.
Positive trends in biomarker data from Aileron's LTI-03 and the completion of enrollment in a Phase 1b trial suggest potential for future drug approval, impacting stock value and market confidence.
Frequently Asked Questions About ALRN Stock
What is Aileron Therapeutics, Inc.'s (ALRN) stock forecast for 2025?
Based on our analysis of 2 Wall Street analysts, Aileron Therapeutics, Inc. (ALRN) has a median price target of $13.00. The highest price target is $19.00 and the lowest is $7.00.
Is ALRN stock a good investment in 2025?
According to current analyst ratings, ALRN has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.01. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ALRN stock?
Wall Street analysts predict ALRN stock could reach $13.00 in the next 12 months. This represents a 546.8% increase from the current price of $2.01. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Aileron Therapeutics, Inc.'s business model?
Aileron Therapeutics focuses on developing innovative treatments for orphan diseases, primarily in the fields of pulmonary and fibrosis indications. The company generates revenue through the advancement of its drug candidates, such as LTI-03 and LTI-01, which are in various stages of clinical trials, with the potential for partnerships or licensing agreements once products are commercialized.
What is the highest forecasted price for ALRN Aileron Therapeutics, Inc.?
The highest price target for ALRN is $19.00 from Aydin Huseynov at Ladenburg Thalmann, which represents a 845.3% increase from the current price of $2.01.
What is the lowest forecasted price for ALRN Aileron Therapeutics, Inc.?
The lowest price target for ALRN is $7.00 from at , which represents a 248.3% increase from the current price of $2.01.
What is the overall ALRN consensus from analysts for Aileron Therapeutics, Inc.?
The overall analyst consensus for ALRN is bullish. Out of 2 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $13.00.
How accurate are ALRN stock price projections?
Stock price projections, including those for Aileron Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
